

Asian Journal of Biochemistry, Genetics and Molecular Biology

Volume 13, Issue 2, Page 22-36, 2023; Article no.AJBGMB.97065 ISSN: 2582-3698

# Variations in Fat-mass and Obesityassociated (FTO) Genes and Allelic Distribution in Some Selected Ethnic Populations in Niger Delta, Nigeria

N. O. Ekpete <sup>a,b\*</sup>, I. Elekima <sup>a</sup>, H. Brown <sup>a</sup>, E. E. Osaji <sup>b</sup>, B. O. Igbinaduwa <sup>b</sup>, P. T. Nnanna <sup>b</sup> and E. O. Nwachuku <sup>a</sup>

<sup>a</sup> Department of Medical Laboratory Science, Rivers State University, Port Harcourt, Rivers State, Nigeria. <sup>b</sup> Federal Medical Centre, Asaba, Delta State, Nigeria.

## Authors' contributions

This work was carried out in collaboration among all authors. Authors NOE, EON and HB designed the study, authors NOE and EON wrote the literature review, while authors HB and IE carried out the statistical analysis and author NOE, EEO, BOI and PTN wrote the first draft of the manuscript and carried out the laboratory analysis. All authors read and approved the final manuscript.

## Article Information

DOI: 10.9734/AJBGMB/2023/v13i2290

**Open Peer Review History:** 

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/97065

> Received: 04/01/2023 Accepted: 09/03/2023 Published: 15/03/2023

Original Research Article

## ABSTRACT

**Aim:** To evaluate variations in FTO genes and allelic distribution in some ethnic populations in Niger Delta, Nigeria.

Study Design: Case-controlled observational study.

**Place and Duration of Study:** Federal Medical Centre, Asaba, Delta State and Safety Molecular Pathology Laboratory, Enugu, Nigeria, between March 2020 and February 2022.

**Methodology:** The association between sixteen (16) Single Nucleotide Polymorphisms in the FTO gene and some biomarkers of obesity and type 2 diabetes subjects (78 cases and 20 controls) from

Asian J. Biochem. Gen. Mol. Biol., vol. 13, no. 2, pp. 22-36, 2023

<sup>\*</sup>Corresponding author: E-mail: shalomnwagodfmc@yahoo.com;

four different tribes in the Niger Delta region, Nigeria. Multistage sampling method was employed in the subject selection. The subjects were first separated into two groups – new cases (less than a year of diagnosis as Diabetic) and old cases (one year & above). Equal number of samples was then randomly collected from each of the cluster groups. Ten millilitres of blood were collected into EDTA for genotyping using Illumina NextSeq 2000 sequencing platform. Hardy-Weinberg Equilibrium statistical test was used to determine the variation in distribution of the alleles and genotypes within the study population while allelic frequencies were calculated by gene counting. Chi-square (and fisher's test where chi-square was not applicable) and Odd Ratio (OR) were performed to determine the significant differences and associated risks respectively of the allelic and genotypic frequencies of Type 2 diabetic (T2D) and non-diabetic subjects of the FTO gene variants.

**Results:** The results of Hardy-Weinberg Statistical Test, Genotype and Allelic Distribution of FTO gene Variants in Obese/T2D Subjects in Different Tribes of Niger Delta are presented in Tables(1-4) for rs73609956 (C>T), rs116753298 (T>C), rs201041270 (A>G), rs531215275 (A>C), rs146056278 (C>T), rs1410999299 (G>A), rs79206939 (A>G), rs145884431(G>A), rs61743972 (G>A), rs201496428 (C>T), rs146138389 (T>C), rs886052102 (A>G), rs144743617 (G>A), rs886052103 (T>A), rs9939609 (A>T) and rs8050136 (A>C). However, no significant differences in analyzed genotype frequencies were found between T2D and healthy controls.

**Conclusion:** Knowledge of the dominant SNPs in some ethnic groups, may provide platform to delay its expression through informed wise choice of lifestyle change and proper dieting.

Keywords: Fat-mass and obesity-associated gene (FTO) variants; allelic distribution; ethnic populations; Niger Delta; Nigeria.

## 1. INTRODUCTION

The FTO gene is of the AlkB related non-haem iron and 2-oxoglutarate-dependent oxygenase superfamily but the exact physiological function of this gene is not known. The Primary (citable) accession number is Q9C0B1. Studies in mice and humans indicate a strong association with body mass index, obesity risk, and type 2 diabetes. Disease susceptibility is associated with variations affecting the gene represented in this entry. It is unclear whether variations associated with obesity directly affect FTO function or alter the expression of adjacent genes such as IRX3, rather than FTO itself. A pathogenic intronic FTO variation (rs1421085) disrupts an evolutionarily conserved motif for ARID5B binding. Loss of ARID5B binding results in overexpression of two genes distal to FTO, IRX3 and IRX5. IRX3 and IRX5 overexpression shifts pre-adipocytes differentiation from brown to white fat cells, resulting in increased lipid storage and loss of mitochondrial thermogenesis [1-3]. FTO is a protein-coding gene located at the chromosome region 16q12.2 and associated with the control of food intake and energy balance [4].

Reports of different studies in different populations or geographical locations, appears to suggest different patterns of association of FTO gene variants with obesity and T2D in varying ethnicities, and several researchers have called for more work in other ethnic populations to determine more precisely the extent of the effects in each ethnic group. In addition, some reports have claimed ethnic-specific associations with alternative SNPs, and to that end there has been a degree of inconsistency [5,6]. There is paucity of data available on the FTO gene allele variants in African and Nigerian Populations. Knowing the FTO gene variants that are common in persons with obesity and T2D in each of the ethnic population to be studied will be adding to the knowledge available in the understanding of the etiology and pathogenesis of these disorders and may be useful in prediction and identifying the possible complications that may arise in patients with these genetic variants. The pathogenesis of obesity and T2D is reportedly related to variations in the fat mass and an obesity-associated gene (FTO); however, as the number of reports increases, particularly with respect to varying ethnicities, there is a need to determine more precisely the nature and extent of the effect of FTO gene polymorphisms in each ethnic group. In addition, some reports have ethnic-specific associations claimed with alternative single nucleotide polymorphisms (SNPs), and to that end there has been a degree of confusion [7].

Genome-wide association studies (GWAS) have identified a number of genetic polymorphisms that are associated with an increased risk for obesity and T2D [8,9]. Also, genome-wide association studies identified a common variant. rs9939609, in the FTO (fat mass and associated obesity) gene that was strongly associated with BMI and obesity in European population [10,11]. The single nucleotide polymorphism rs9939609 of the gene FTO, which encodes fat mass and obesity-associated protein, is stronalv associated with obesity and type 2 diabetes (T2D) in multiple populations; however, the underlying mechanism of this association is unclear [12]. Findings by Liu et al. [13] indicate that the two variants (rs9939609 and rs8050136) in the FTO gene contribute to obesity and T2D in the Asian populations. The aim of this study was to evaluate variations in FTO genes and allelic distribution in some ethnic populations in Niger Delta, Nigeria

## 2. MATERIALS AND METHODS

## 2.1 Study Area

The study was carried out in Niger Delta region of Nigeria, with Federal Medical Centre, Asaba serving as the major point of the sample collection and some analysis. Some samples were also collected at Agbor & Bomadi. The Igbo participants were drawn from the Igbos of Delta State, Rivers State and Imo State; the Ijaw participants were drawn from the Ijaws of Delta State, Bayelsa State and Rivers State.

The Niger Delta was once known as the Oil Rivers, Nigeria's Niger Delta region is a very densely populated region, a major palm oil producer. After its expansion, it became the Niger Coast Protectorate. Stretching directly on the Gulf of Guinea on the Atlantic Ocean in Nigeria, the Niger Delta used to be historically made up of present-day Bayelsa, Rivers, and Delta states are today, made up of nine coastal states. The federal government of Nigeria's current definition states that the delta extends over about seventy thousand km<sup>2</sup> and makes up almost 7 percent of its landmass. The Niger Delta comprises of level low lying muggy landscape that is befuddled by wandering and anastomosing streams, waterways and brooks [14,15].

Asaba, the capital city of Delta State, Nigeria is situated within geographical co-ordinates 6°11′52.23″N6°43′42.48″E. It is situated on a terrace of the lower Niger River, overlooking the point where the Anambra River flows into it. Beyond the river banks, on the high plains which are far more extensive than the river basins, secondary forest vegetation flourishes.

## 2.2 Research Design

This is a case-controlled observational study involving the evaluation of FTO gene allele variants and allelic distribution in some ethnic groups in Niger Delta, Nigeria. The bio-data and medical history of the subjects were obtained using questionnaire, measuring their weight with a calibrated weighing scale, height and waist circumference.

## 2.3 Sample Size

A total of 98 subjects enrolled for this study. The sample size was obtained using the formular stated below:

$$\mathsf{N} = \frac{Z^2 p q}{d^2}$$

N = The desired sample size

Z = The Standard Normal deviate usually set at 1.962 corresponding to the 95% Confidence level p = The SNPs Prevalence rates. (Minor Alleles Frequency of SNPs set at >0.02).

q = 1- p

d = degree of accuracy desired set at 0.05

Minimum Size – 30

By adding 10% of non-respondent = 33

## 2.4 Sampling Method

Multistage sampling method was employed in the subject selection. The subjects were first separated into two groups – new cases (less than a year of diagnosis as Diabetic) and old cases (one year & above). Equal number of samples was then randomly collected from each of the cluster groups.

## 2.5 Selection Criteria

#### 2.5.1 Inclusion criteria

Individuals who are purebred of the selected tribes in Niger Delta, aged at least 21 years diagnosed with T2D for at least one year. Controls: Individuals who are from the selected tribes with no history of diabetes, and a fasting blood glucose of less than 6.5mmol/l. The cluster groups were considered also.




Fig. 1. Political map of the Niger Delta area

### 2.5.2 Exclusion criteria

Individuals not of the selected tribes, those who are not purebred from the selected tribes, those who are critically ill subjects and female participants who are pregnancy.

#### 2.6 Sample Collection and Analysis

#### 2.6.1 Sample collection

Ten millilitres (10ml) of blood were randomly collected from 19-20 subjects from each of the tribes following selected the sampling methodology described earlier and 20 control made of 5 non-diabetic, non-obese subjects from each of the selected tribes. This was after completing the questionnaire and signing the consent form. Their body weight in kilogram. height in meter and waist circumference in centimeter were also measured and recorded. Four mI of blood was collected using a EDTA K<sub>3</sub> tubes and was transported in cold box to Safety Molecular Pathology Laboratory Services located at 44 Rangers Avenue, Enugu for DNA extraction and genotyping (Sequencing).

#### 2.6.2 Sample Analysis

#### 2.6.2.1 Genetic analysis

**Genomic DNA extraction:** Genomic DNA extractions of the samples was performed using Geneaid DNA Mini Kit (Blood/Cultured Cell).

Principle: RBC Lysis Buffer and chaotropic salt are used to lyse cells and degrade protein, allowing DNA to bind to the glass fiber matrix of the spin column. Contaminants are removed using a wash buffer (containing ethanol) and the purified genomic DNA is eluted by a low salt elution buffer, TE or water. The entire procedure can be completed within 25 minutes without phenol/chloroform extraction or alcohol precipitation. The purified DNA, with approximately 20-30 kb, is suitable for use in PCR or other enzymatic reactions.

## Stage 1: Guanidinium thiocyanate or guanidinium isothiocyanate (GITC) procedure

One millitres of whole blood sample was transferred into a 15mL tube and labelled accordingly.

Ten millitres of cold 1x Red blood cell lysis buffer (RCLB) was added to each sample and the tube properly closed and was mixed by inversion. The tube was then placed on ice for 10 minutes. The tubes were wiped carefully. The tubes were centrifuged at 4000 rpm for 7 minutes. The supernatant was carefully decanted into the waste bucket. Care was taken not to lose the cell pellet.

Ten millitres of cold 1x RCLB was again added to the cell pellet, mixed by vortexing as describe above. Where there were still traces of red cells, 10ml of cold RCLB was added to the cell pellet again, mixed by vortexing as described above.

Ten millilitres of sterile Phosphate buffered saline (PBS) was added to the cell pellet, mixed by vortexing and centrifuged at 4000 rpm for 7min.

The supernatant was decanted; 5ml of sterile PBS was added into each tube. Mixed by vortexing and centrifuged at 4000rpm for 5min.

The supernatant was decated into the waste bucket carefully not to discard the pellet and the fifteen millilitres tubes were drained on a clean towel. While draining, the GITC buffer was prepared by adding 10uL beta-mercaptoethanol (BME) to the 1ml of GITC. One millilitre of activated GITC buffer containing BME was added to the cell pellets in one tube.

A blunt end 18G needle and 2ml syringe was used to homogenise the GITC lysate 18 times.

A sterile Pasteur pipettes was used to transfer the GITC lysate into 2mL cryovial and labelled accordingly for storage at minus -20<sup>o</sup>C. (The lysate can also be used immediately for nucleic acid extraction).

For quality control (QC) purpose, also 1.0mL of the GITC buffer containing BME was transferred into a cryovial, label as QC control and treated as a sample during nucleic acid extractions.

Stage 2: DNA Extraction [Geneaid Genomic DNA Mini Kit (Blood/Cultured Cell)]

#### **Protocol for Extraction:**

Two hundred microlitres of GITC lysate was pipetted into a 1.5mL tube.

Two hundred and fifty microliters of Guanidium Chloride buffer (GB buffer), and vortexed for 15 seconds and then incubated at 60°C for 30mins. It was mixed occasionally.

Two hundred and fifty microliters absolute ethanol was added and Vortexed gently for 10 seconds.

The mixture was incubated at room temp for 5 minutes.

The GD column was placed in 2mL collection tube. The mixture was transferred into the GD column.

It was centrifuged at 14000 rpm for 5 minutes.

The 2mL collection tube was discarded and then replaced with a new one.

Four hundred microlitres of W1 buffer was added to the GD column and centrifuged for 1 minute.

The collection tube was discarded and the GD column was placed in a new collection tube.

Six hundred microlitres of wash buffer was added to the GD column and centrifuged for 1 minute.

The GD column was place into another collection tube, centrifuged at 14000rpm for 3 minutes to ensure the column is dry.

The GD column was transferred to 1.5ml tube.

Sixty microlitres of preheated elution buffer was added to the center of the GD column and allowed to stand for 10 minutes at room temperature.

Then centrifuged at 14000 rpm for 30 seconds to elute the purified DNA.

## 2.6.2.2 Genotyping of SNPs

Genotyping of SNPs of the FTO gene was performed with the Illumina next-generation sequencing (NGS) using NextSeq 2000 Sequencing System. Purity and concentration of isolated DNA was determined by UV/VIS spectrophotometer NanoDrop ND-1000. The primers for the sequence, as designed from Illumina Design Studio (Ampliseq for Illumina Gene DNA for FTO Gene with a 100% coverage):

The primers for the sequence, as designed from Illumina Design Studio (Ampliseq for Illumina Gene DNA for FTO Gene with a 100% coverage):

Manifest IAA23693\_182 Manifest Format Version 1.0 Manifest File Version 20201117 BuildID grch38.p2 source ConvertTsaManifestLite 1.22.0.388

## 2.7 Statistical Analysis

Hardy-Weinberg Equilibrium statistical test was used to determine the variation in distribution of the alleles and genotypes within the study population while allelic frequencies were calculated by gene counting. Chi-square (and fisher's test where chi-square was not applicable) and Odd Ratio (OR) were performed to determine the significant differences and associated risks respectively of the allelic and genotypic frequencies of Type 2 diabetic (T2D) and non-diabetic subjects of the FTO gene variants. Statistical significance was set at p<0.05.

## 3. RESULTS AND DISCUSSION

This study investigated the association of FTO gene variants in the Niger Delta region in Southern Nigeria, involving several FTO gene variants. Sixteen (16) variants common to all the Niger Delta tribes was identified after sequencing and analysed after excluding some that significantly deviated from Hardy-Weinberg equilibrium, in this novel study of the FTO gene in that region. They are rs73609956, rs11 6753298, rs201041270, rs531215275, rs 146 056278, rs1410999299, rs79206939, rs 14588 4431, rs61743972, rs201496428, rs 14613 8389, rs886052102, rs144743617, rs 886 052103, rs9939609 and rs8050136. These are SNPs have been found in previous studies involving European African population, and Asian populations [10,16-19].

Most FTO SNPs in all the tribes (Tables 1-4) by the deviation values showed weak linkage disequilibrium (LD) except for the FTO SNPs in the first intron of the gene such as rs9939609 which showed a high LD as against findings in populations of European ancestry and African American. This is consistent with the findings by other studies in Sub-Sahara Africa and amongst the Malaysian Malays [17-18]. The potential explanation to this may be in the homogeneity of passage along ancestral line through intra tribe marriages and low migration as against what obtains in Europe and our study subjects are also purebreds.

The analysis observed minor allele frequency (MAF) consistent with other findings in African populations much lower than those reported for European populations [16-17] and a similar allelic or genotype frequencies with ten FTO SNPs between the case and control in all the tribes (Tables 5-20). The MAF for the rs9939609 FTO

gene variants in the Niger Delta population from this study is approximately 21% (Tables 4 and 18) with about 15% carrying the risk allele (A). The FTO variant MAF in white Europeans is put at approximately 45%, such that 66% of Europeans carry at least one risk allele and 18% carry two risk alleles [20]. The prevalence of the risk alleles of rs9939609 FTO SNP in East Asians (approx. 20%) and South Asians (approx. 30%) is substantially lower than in Europeans [21]. Peng et al. [22] in a meta-analysis of several studies for five FTO polymorphs, estimated the MAF for control subjects across all studies to be within the range of 11-45%, 40-46%, 11-44%, 36-60% and 21-44% for rs9939606, rs1421085, rs8050136, rs17817449 and rs1121980 respectively. A meta-analysis reported that the minor allele frequency (MAF) for rs9939609 varies across the alobal population. Apalasamy et al. [18] found the MAF of the FTO rs9939609 polymorphism was lower (0.31) in the Malaysian Malay population compared to the previously reported range of 0.38 to 0.46 in European population. Grant et al. in a study in 2008 found a varied frequencies among African-American unlike what was observed by this study, while Henning et al. 2009 in a study in an African population found otherwise. The discrepancies in the African-American was attributed to the genetically heterogeneous nature of the population as against the study nature of the study by Henning and colleagues which was in West Kiage region of Gambia which is ethnically homogenous.

The findings in this study however, observed a significant distribution difference mostly with the dominant allele with rs146056278 (TT,T; p<0.04) in Ika, rs1410999299 [(AA+AG, p<0.04), (A, p<0.03)] in Ika, rs79206939 (GG+GA, p<0.04), rs146138389 (CC, C, p<0.04), rs886052102 (GG, G, p<0.04) in Ika and Igbo tribes and rs8050136 (CC, C, p<0.002) in the ljaw tribes. Bressler et al. [23] observed there was significant difference in four FTO genotype (rs9939609, rs17817449, rs805136, rs1421085) frequencies in the whites, but a difference was only revealed for one (rs1421085) in African-American. Apalasamy et al. [18] in a study among the Malays of Malaysia observed no significant differences in allelic or genotype between the obese and non-obese groups.

#### Table 1. Hardy-weinberg statistical test of FTO gene variants of FTO gene in obese|T2D subjects in different tribes of Niger Delta

FTO gene Variant		rs73609956 (C	>T)		rs116753298	(T>C)	r	s201041270 (	A>G)	rs	531215275	(A>C)
Genotype	TT	CT	CC	CC	СТ	TT	GG	GA	AA	CC	CA	AA
No, Obs	92	6	0	92	6	0	92	6	0	89	9	0
Freq, Allele	0.97	-	0.03	0.97	-	0.03	0.97	-	0.03	0.95	-	0.05
Freq, Exp	0.94	0.06	0.0009	0.94	0.06	0.0009	0.94	0.06	0.0009	0.90	0.01	0.003
No, Exp	92.12	5.88	0.09	92.12	5.88	0.09	92.12	5.88	0.09	88.2	0.98	0.3
Deviation	-0.12	0.12	-0.09	-0.12	0.12	-0.09	-0.12	0.12	-0.09	0.8	8.02	-0.3
X <sup>2</sup>	0.0002	0.002	0.99	0.0002	0.002	0.99	0.0002	0.002	0.99	0.007	0.69	0.3

T|C|G|C=wild (Dominant), C|T|A|A=Polymorphic,  $X^2$  =chi-square, Exp=Expected, Obs=Observations

#### Table 2. Hardy-Weinberg Statistical Test of FTO gene Variants of FTO gene in Obese|T2D subjects in Different Tribes of Niger Delta

FTO gene Variant		rs146056278	(C>T)		rs1410999299	(G>A)		rs7920693	9 (A>G)	rs14	5884431 (	G>A)
Genotype	TT	СТ	CC	AA	AG	GG	GG	GA	AA	AA	GA	GG
No, Obs	95	3	0	92	5	1	93	4	1	90	8	0
Freq, Allele	0.98	-	0.02	0.96	-	0.04	0.97	-	0.03	0.96	-	0.04
Freq, exp	0.97	0.04	0.0004	0.93	0.08	0.002	0.94	0.06	0.0009	0.92	0.08	0.002
No, Exp	95	3.84	0.04	91.13	7.53	0.2	92.09	3.94	0.09	90.32	7.84	0.2
Deviation	1	-0.84	-0.04	0.88	-2.53	0.8	0.91	0.06	0.91	-0.32	1.6	-0.2
X <sup>2</sup>	0.01	0.18	0.04	0.008	0.85	0.14	0.009	0.0009	0.99	0.001	0.34	0.66

T|A|G|A=wild (Dominant), C|G|A|G=Polymorphic,  $X^2$  =chi-square, Exp=Expected, Obs=Observations

#### Table 3. Hardy-weinberg statistical test of FTO gene variants of FTO gene in obese|T2D subjects in different tribes of Niger Delta

FTO gene Variant		rs61743972	(G>A)		rs201496428 (	(C>T)		rs146138389 (T	「>C)		rs886052102	(A>G)
Genotype	AA	GA	GG	TT	СТ	CC	CC	TC	TT	GG	GA	AA
No, Obs	92	6	0	92	6	0	91	7	0	92	6	0
Freq, Allele	0.97	-	0.03	0.97	-	0.03	0.96	-	0.04	0.97	-	0.03
Freq, exp	0.94	0.06	0.0009	0.94	0.06	0.0009	0.93	0.08	0.02	0.94	0.06	0.0009
No, Exp	92.12	5.88	0.09	92.12	5.88	0.09	91.14	7.84	1.96	92.12	5.88	0.09
Deviation	-0.12	0.12	-0.09	-0.12	0.12	-0.09	-0.14	-0.84	-1.96	-0.12	0.12	-0.09
X <sup>2</sup>	0.0002	0.002	0.99	0.0002	0.002	0.99	0.0002	0.09	0.91	0.0002	0.002	0.99

A|T|G|G=wild (Dominant), G|C|T|A=Polymorphic, X<sup>2</sup> =chi-square, Exp=Expected, Obs=Observations

#### Table 4. Hardy-weinberg statistical test of FTO gene variants of FTO gene in obese|T2D subjects in different tribes of Niger Delta

FTO gene Variant		rs144743617	′ (G>A)		rs886052103 (	T>A)		rs9939609 (A>	•T)		rs8050136	(A>C)
Genotype	AA	GA	GG	AA	TA	TT	TT	AT	AA	CC	AC	AA
No, Obs	93	5	0	92	6	0	77	12	9	81	17	0
Freq, Allele	0.98	-	0.02	0.97	-	0.03	0.85	-	0.15	0.91	-	0.09
Freq, exp	0.96	0.03	0.0004	0.94	0.06	0.0009	0.72	0.26	0.02	0.83	0.16	0.008
No, Exp	94	2.94	0.03	92.12	5.88	0.09	70.6	25.48	1.96	81.34	15.68	0.8
Deviation	1	2.06	-0.03	-0.12	0.12	-0.09	6.4	13.48	7.04	-0.34	2.68	-0.8
X <sup>2</sup>	0.01	1.44	0.03	0.0002	0.002	0.99	0.5	0.26	0.25	0.001	0.5	0.6

A|A|T|C=wild (Dominant), G|T|A|A=Polymorphic,  $X^2$  =chi-square, Exp=Expected, Obs=Observations

## Results of Genotypic and Allelic Distribution of FTO gene Variants in Obese|T2D Subjects in Different Tribes of Niger Delta:

Tribes Ρ OR X<sup>2</sup> P OR X2 Ρ OR OR ljaw X<sup>2</sup> Urhobo lka lgbo X² Ρ NDn=5 Genotype T2Dn=19 NDn=5 T2Dn=19 NDn=5 T2Dn=20 NDn=5 T2Dn=20 TT 18(94.7%) 5(100%) 19(100%) 5 (100%) 20(100%) 5 (100%) >0.99 18 (90%) 5 (100%) >0.99 ------СТ 1 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2(10%) 0 (0.0%) CC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) ΤT 18(94.7%) 5 (100%) 0.27 0.60 0.00 19 100%) 5 (100%) 20(100%) 5 (100%) >0.99 18 (90%) 5 (100%) 0.54 0.46 0.00 -CT + CC 1 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (10%) 0 (0.0%) TT+CT 5 5 (100%) 5 (100%) 20(100%) 5 (100%) 19 >0.99 19(100%) 20(100%) >0.99 >0.99 СС 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 10(100%) Т 37(97.4%) 0.26 0.60 0.00 38(100%) 10(100%) >0.9 40(100%) 10(100%) >0.99 38(95%) 10(100%) 0.52 0.47 0.00 С 0 (0.0%) 2(5%) 0 (0.0%) 1(2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)

Table 5. Genotype and Allele Distribution of rs73609956 Variant of FTO gene in Obese|T2D subjects in Different Tribes of Niger Delta

T=wild (Dominant), C=Polymorphic, T2D=Type 2 Diabetes, ND = Non- Diabetes (control), X =chi-square, p= p value, OR= Odd Ratio

#### Table 6. Genotype and allele distribution of rs116753298 variant of FTO gene in obese|T2D subjects in different tribes of Niger Delta

Tribes	lja	w	X²	Р	OR	Urhobo		X <sup>2</sup>	Р	OR	lk	a	X²	Р	OR	Igl	bo	X²	Р	OR
Genotype	T2Dn=19	NDn=5	-	-	-	T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
CC	17(89.5%)	5(100%)				18(94.7%)	5 (100%)	-	-	-	19(95%)	4 (80%)	-	-	-	19(95%)	5(100%)	-	-	-
CT	2 10.5%)	0 (0.0%)				1 (5.2%)	0 (0.0%)				1 (5%)	1 (20%)				1 (5%)	0 (0.0%)			
TT	0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)			
CC	17(89.5%)	5(100%)	0.57	0.45	0.0	18(94.7%)	5 (100%)	0.27	0.60	0.0	19 (95%)	4 (80%)	1.22	0.27	4.8	19(95%)	5(100%)	0.27	0.60	0.0
CT + TT	2 (10.5%)	0 (0.0%)				1 (5.2%)	0 (0.0%)				1 (5%)	1 (20%)				1 (5%)	0 (0.0%)			
CC+CT	19 (100%)	5(100%)		>0.99		19 100%)	5 (100%)		>0.99		20(100%)	5(100%)		>0.99		20100%)	5(100%)		>0.99	
TT	0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)				0(0.0%)	0 (0.0%)			
С	36(94.7%)	10(100%)	0.55	0.47	0.0	37(94.7%)	10(100%)	0.26	0.60	0.0	39(97.5%)	9(90%)	1.17	0.28	4.3	39(97.5%)	10(100%)	0.26	0.61	0.0
Т	2 (5.3%)	0 (0.0%)				1 (5.2%)	0 (0.0%)				1 (2.5%)	1 (10%)				1 (2.5%)	0 (0.0%)			

C=wild (Dominant), T=Polymorphic, T2D=Type 2 Diabetes, ND = Non- Diabetes (control), X<sup>2</sup> =chi-square, p= p value, OR= Odd Ratio

	lja	w	X <sup>2</sup>	Р	OR	Urh	obo	X <sup>2</sup>	Р	OR	I	ka	X <sup>2</sup>	Р	OR	lg	bo	X <sup>2</sup>	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
GG	17(89.5%)	5 100%)	-	-	-	18(94.7%)	5(100%)	-	-	-	19 (95%)	5(100%)	-	-	-	18 (90%)	5 100%)	-	-	-
GA	2 (10.5%)	0 (0.0%)				1 (5.2%)	0 (0.0%)				1 (5%)	0 (0.0%)				2 (10%)	0 (0.0%)			
AA	0(0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)			
GG	17(89.5%)	5(100%)	0.57	0.45	0.0	18(94.7%)	5(100%)	0.27	0.60	0.0	19 (95%)	5(100%)	0.27	0.60	0.0	18 (90%)	5(100%)	0.11	0.73	0.0
GA + AA	2 (10.5%)	0 (0.0%)				1 (5.2%)	0 (0.0%)				1 (5%)	0 (0.0%)				2 (10%)	0 (0.0%)			
GG+GA	19 (100%)	5(100%)	-	>0.99	-	19 (100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
AA	0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)				0 (0.0%)	0 (0.0%)			
G	36(94.7%)	10(100%)	0.54	0.45	0.0	37 94.7%)	10(100%)	0.26	0.60	0.0	39(97.5%)	10(100%)	0.25	0.61	0.0	38 (95%)	10(100%)	0.52	0.47	0.0
А	2 (5.2%)	0 (0.0%)				1 (5.2%)	0 (0.0%)				1 (2.5%)	0 (0.0%)				2 (5%)	0 (0.0%)			

## Table 7. Genotype and allele distribution of rs201041270 variant of FTO gene in obese|T2D subjects in different tribes of Niger Delta

G=wild (Dominant), A=Polymorphic, T2D=Type 2 Diabetes, ND = Non- Diabetes (control),  $X^{2}$  =chi-square, p= p value, OR= Odd Ratio

## Table 8. Genotype and allele distribution of rs531215275 variant of FTO gene in obese|T2D subjects in different tribes of Niger Delta

Tribes	lj	aw	X <sup>2</sup>	Р	OR	Urh	obo	X <sup>2</sup>	Р	OR	Ił	a	X <sup>2</sup>	Р	OR	lg	bo	X <sup>2</sup>	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
CC	17(89.5%)	5(100%)	-	-	-	17(89.5%)	4(80%)	-	-	-	19(95%)	5(100%)	-	-	-	18(90%)	4(80%)	-	-	-
CA	2(10.5%)	0(0.0%)				2(10.5%)	1(20%)				1(5%)	0(0.0%)				2(10%)	1(20%)			
AA	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
CC	17(89.5%)	5(100%)	0.57	0.45	0.00	17(89.5%)	4(80%)	0.32	0.57	2.13	19(95%)	5(100%)	0.27	0.60	0.00	18(90%)	4(80%)	0.37	0.53	2.25
CA+AA	2(10.5%)	0(0.0%)				2(10.5%)	1(20%)				1(5%)	0(0.0%)				2(10%)	1(20%)			
CC+CA	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
AA	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
С	36(94.7%)	10(100%)	0.55	0.45	0.00	36(94.7%)	10(100%)	0.55	0.45	0.00	39(97.5%)	10(100%)	0.25	0.61	0.00	38(95%)	10(100%)	0.52	0.47	0.00
A	2(5.2%)	0(0.0%)				2(5.2%)	0(0.0%)				1(2.5%)	0(0.0%)				2(5%)	0(0.0%)			

C=wild(Dominant), A=Polymorphic, T2D=Type2Diabetes, ND=Non-Diabetes(control), X<sup>2</sup>=chi-square, p=pvalue, OR=OddRatio

#### Table 9.Genotype and allele distribution of rs146056278 variant of FTO genein obese|T2D subjects in differenttribes of Niger Delta

Tribes	lja	aw	X²	Р	OR	Urh	obo	X²	Р	OR	lk	a	X <sup>2</sup>	Р	OR	lg	bo	X <sup>2</sup>	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
TT	19(100%)	5(100%)	-	-	-	19(100%)	5(100%)	-	-	-	20(100%)	4(80%)	-	-	-	18(90%)	5(100%)	-	-	-
тс	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	1(20%)				2(10%)	0(0.0%)			
CC	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
TT	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	4(80%)	4.17	0.04	<0.0	18(90%)	5(100%)	0.54	0.46	0.000
TC+CC	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	1(20%)				2(10%)	0(0.0%)			
TT+TC	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
CC	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
Т	38(100%)	10(100%)	-	>0.99	-	38(100%)	10(100%)	-	>0.99	-	40(100%)	9(90%)	4.17	0.04	<0.0	38(95%)	10(100%)	0.52	0.47	0.00
С	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	1(10%)				2(5%)	0(0.0%)			
					T=wild	d(Dominant).C=F	Polymorphic T2	D=Tvne	2Diabetes	ND=Non-	Diabetes(contro	) X <sup>2</sup> =chi-squa	re n=nval	ue OR=Od	dRatio					

T=wild(Dominant),C=Polymorphic,T2D=Type2Diabetes,ND=Non-Diabetes(control),X<sup>\*</sup>=chi-square,p=pvalue,OR=OddRation

Tribes	lja	w	X <sup>2</sup>	Р	OR	Urh	obo	X <sup>2</sup>	Р	OR	lka	a	X <sup>2</sup>	Р	OR	Igi	bo	X <sup>2</sup>	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
AA	17(89.5%)	5100%)	-	-	-	18(94.7%)	5(100%)	-	-	-	19(95%)	4(80%)	-	-	-	19(95%)	5(100%)	-	-	-
AG	2(10.5%)	0(0.0%)				1(5.2%)	0(0.0%)				1(5%)	0(0.0%)				1(5%)	0(0.0%)			
GG	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	1(20%)				0(0.0%)	0(0.0%)			
AA	17(89.5%)	5100%)	0.57	0.45	0.0	18(94.7%)	5(100%)	0.27	0.60	0.0	19(95%)	4(80%)	0.28	0.59	2.25	19(95%)	5(100%)	0.27	0.60	0.0
AG+GG	2(10.5%)	0(0.0%)				1(5.2%)	0(0.0%)				1(5%)	1(20%)				1(5%)	0(0.0%)			
AA+AG	19(100%)	5100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	4(80%)	4.17	0.04	<0.0	20(100%)	5(100%)	-	>0.99	-
GG	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	1(20%)				0(0.0%)	0(0.0%)			
А	36(94.7%)	10(100%)	0.55	0.45	0.0	37(94.7%)	10(100%)	0.26	0.60	0.0	39(97.5%)	8(80%)	4.34	0.03	9.75	39(97.5%)	10(100%)	0.26	0.61	0.0
G	2(5.2%)	0(0.0%)				1(5.2%)	0(0.0%)				1(2.5%)	2(20%)				1(2.5%)	0(0.0%)			

#### Table 10. Genotype and allele distribution of rs1410999299 variant of FTO geneinobese|T2D subjects in different tribes of Niger Delta

A=wild(Dominant),G=Polymorphic,T2D=Type2Diabetes,ND=Non-Diabetes(control),X<sup>2</sup>=chi-square,p=pvalue,OR=OddRatio

#### Table 11. Genotype and allele distribution of rs79206939 variant of FTO geneinobese|T2D subjects in different tribes of NigerDelta

Tribes	lja	w	X <sup>2</sup>	Р	OR	Urh	obo	X²	Р	OR	II	ka	X <sup>2</sup>	Р	OR	lgt	00	X <sup>2</sup>	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
GG	18(94.7%)	5(100%)	-	-	-	19	5(100%)	-	-	-	18(90%)	4(80%)	-	-	-	19(95%)	5(100%)	-	-	-
GA	1(5.2%)	0(0.0%)				0(0.0%)	0(0.0%)				2(10%)	0(0.0%)				1(5%)	0(0.0%)			
AA	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	1(20%)				0(0.0%)	0(0.0%)			
GG	18(94.7%)	5(100%)	0.27	0.60	0.00	19(100%)	5(100%)	-	>0.99	-	18(90%)	4(80%)	0.38	0.53	2.25	19(95%)	5(100%)	0.27	0.60	0.00
GA+AA	1(5.2%)	0(0.0%)				0(0.0%)	0(0.0%)				2(10%)	1(20%)				1(5%)	0(0.0%)			
GG+GA	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	4(80%)	4.17	0.04	<0.0	20(100%)	5(100%)	-	>0.99	-
AA	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	1(20%)				0(0.0%)	0(0.0%)			
G	37(94.7%)	10(100%)	0.26	0.60	0.00	38(100%)	10(100%)	-	>0.99	-	38(95%)	8(80%)	2.44	0.11	4.75	39(97.5%)	10(100%)	0.26	0.61	0.00
A	1(5.2%)	0(0.0%)				0(0.0%)	0(0.0%)				2(5%)	2(20%)				1(2.5%)	0(0.0%)			

 $G=wild(Dominant), A=Polymorphic, T2D=Type2Diabetes, ND=Non-Diabetes(control), X^{2}=chi-square, p=pvalue, OR=OddRational Actional Action$ 

#### Table 12. Genotype and allele distribution of rs145884431 Variant of FTO genein Obese|T2D subjects in different tribes of NigerDelta

Tribes	lja	w	X <sup>2</sup>	Р	OR	Urho	obo	X <sup>2</sup>	Р	OR	I	ka	X <sup>2</sup>	Р	OR	lg	bo	X <sup>2</sup>	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
AA	17(89.5%)	5(100%)	-	-	-	17(89.5%)	4(80%)	-	-	-	18(90%)	5(100%)	-	-	-	19(95%)	5(100%)	-	-	-
GA	2(10.5%)	0(0.0%)				2(10.5%)	1(20%)				2(10%)	0(0.0%)				1(5%)	0(0.0%)			
GG	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
AA	17(89.5%)	5(100%)	0.57	0.45	0.0	17(89.5%)	4(80%)	0.32	0.56	2.13	18(90%)	5(100%)	0.27	0.60	0.0	19(95%)	5(100%)	0.27	0.60	0.0
GA+GG	2(10.5%)	0(0.0%)				2(10.5%)	1(20%)				2(10%)	0(0.0%)				1(5%)	0(0.0%)			
AA+GA	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
GG	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
A	36(94.7%)	10(100%)	0.55	0.45	0.0	36(94.7%)	9(90%)	0.30	0.58	2.0	38(95%)	10(100%)	0.52	0.47	0.0	39(97.5%)	10(100%)	0.26	0.61	0.0
G	2(5.2%)	0(0.0%)				2(5.2%)	1(10%)				2(5%)	0(0.0%)				1(2.5%)	0(0.0%)			

A= wild (Dominant), G=Polymorphic, T2D=Type2Diabetes, ND=Non-Diabetes(control), X<sup>2</sup>=chi-square, p=pvalue, OR=Odd Ratio

Tribes	lja	IW	X²	Р	OR	Urh	obo	X <sup>2</sup>	Р	OR	II	ka	X²	Р	OR	Igi	bo	X²	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
AA	17(89.5%)	5(100%)	-	-	-	18(94.7%)	5(100%)	-	-	-	18(90%)	5(100%)	-	-	-	19(95%)	5(100%)	-	-	-
GA	2(10.5%)	0(0.0%)				1(5.2%)	0(0.0%)				2(10%)	0(0.0%)				1(5%)	0(0.0%)			
GG	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
AA	17(89.5%)	5(100%)	0.57	0.45	0.00	18(94.7%)	5(100%)	0.27	0.60	0.00	18(90%)	5(100%)	0.27	0.60	0.00	19(95%)	5(100%)	0.27	0.60	0.00
GA+GG	2(10.5%)	0(0.0%)				1(5.2%)	0(0.0%)				2(10%)	0(0.0%)				1(5%)	0(0.0%)			
AA+GA	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
GG	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
А	36(94.7%)	10(100%)	0.55	0.45	0.00	37(94.7%)	10(100%)	0.26	0.60	0.00	38(95%)	10(100%)	0.52	0.47	0.00	39(97.5%)	10(100%)	0.26	0.61	0.00
G	2(5.2%)	0(0.0%)				1(5.2%)	0(0.0%)				2(5%)	0(0.0%)				1(2.5%)	0(0.0%)			

#### Table 13. Genotype and Allele Distribution of rs61743972 Variant of FTO genein obese|T2D subjects in different tribes of Niger Delta

A=wild(Dominant), G=Polymorphic, T2D=Type2Diabetes, ND=Non-Diabetes(control), X<sup>2</sup>=chi-square, p=pvalue, OR=OddRatio

#### Table 14. Genotype and allele distribution of rs201496428 variant of FTO genein Obese |T2D subjects in different tribes of Niger Delta

Tribes	lja	w	X2	Р	OR	Uhr	obo	X2	Р	OR	IF	ka	X <sup>2</sup>	Р	OR	lg	bo	X²	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
TT	17(89.5%)	5(100%)	-	-	-	16(89%)	5(100%)	-	-	-	19(95%)	5(100%)	-	-	-	20(100%)	5(100%)	-	-	-
CT	2(10.5%)	0(0.0%)				3(11%)	0(0.0%)				1(5%)	0(0.0%)				0(0.0%)	0(0.0%)			
CC	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
TT	17(89.5%)	5(100%)	0.57	0.45	0.00	16(89%)	5(100%)	0.90	0.34	0.00	19(95%)	5(100%)	0.27	0.60	0.00	20(100%)	5(100%)	-	>0.99	-
CT+CC	2(10.5%)	0(0.0%)				3(11%)	0(0.0%)				1(5%)	0(0.0%)				0(0.0%)	0(0.0%)			
TT+CT	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
CC	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
Т	36(94.7%)	10(100%)	0.55	0.45	0.00		10(100%)	0.84	0.36	0.00	39(97.5%)	10(100%)	0.26	0.61	0.00	40(100%)	10(100%)	-	>0.99	-
С	2(5.2%)	0(0.0%)				3(7.9%)	0(0.0%)				1(2.5%)	0(0.0%)				0(0.0%)	0(0.0%)			

T=wild (Dominant), C=Polymorphic, T2D=Type2 Diabetes, ND=Non-Diabetes(control),  $\chi^2$ =chi-square, p=pvalue, OR=OddRatio

#### Table 15. Genotype and allele distribution of rs146138389 variant of FT ogenein obese|T2D subjects in different tribes of Niger Delta

lja	w	X <sup>2</sup>	Р	OR	Urh	obo	X <sup>2</sup>	Р	OR		ka	X <sup>2</sup>	Р	OR	lgb	00	X <sup>2</sup>	Р	OR
T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
19(100%)	4(80%)	-	-	-	17(89.5%)	5(100%)	-	-	-	18(90%)	5(100%)	-	-	-	19(95%)	4(80%)	-	-	-
0(0.0%)	1(20%)				2(10.5%)	0(0.0%)				2(10%)	0(0.0%)				1(5%)	1(20%)			
0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
19(100%)	4(80%)	3.96	0.04	0.0	17(89.5%)	5(100%)	0.57	0.45	0.0	18(90%)	5(100%)	0.27	0.60	0.00	19(95%)	4(80%)	1.22	0.26	4.75
0(0.0%)	1(20%)				2(10.5%)	0(0.0%)				2(10%)	0(0.0%)				1(5%)	1(20%)			
19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
38(100%)	9(90%)	3.88	0.04	0.0	36(94.7%)	10(100%)	0.55	0.45	0.0	38(95%)	10(100%)	0.52	0.47	0.00	39(97.5%)	9(90%)	1.17	0.27	4.33
0(0.0%)	1(10%)				2(5.2%)	0(0.0%)				2(5%)	0(0.0%)				1(2.5%)	1(10%)			
	<b>T2Dn=19</b> 19(100%) 0(0.0%) 0(0.0%) 19(100%) 0(0.0%) 19(100%) 0(0.0%) 38(100%)	$\begin{array}{cccc} 19(100\%) & 4(80\%) \\ 0(0.0\%) & 1(20\%) \\ 0(0.0\%) & 0(0.0\%) \\ 19(100\%) & 4(80\%) \\ 0(0.0\%) & 1(20\%) \\ 19(100\%) & 5(100\%) \\ 19(100\%) & 5(100\%) \\ 0(0.0\%) & 0(0.0\%) \\ 38(100\%) & 9(90\%) \end{array}$	T2Dn=19 NDn=5   19(100%) 4(80%) -   0(0.0%) 1(20%) 0(0.0%)   19(100%) 4(80%) 3.96   0(0.0%) 1(20%) 19(100%)   19(100%) 5(100%) -   0(0.0%) 0(0.0%) -   0(0.0%) 0(0.0%) -   0(0.0%) 9(90%) 3.88	T2Dn=19 NDn=5   19(100%) 4(80%) - -   0(0.0%) 1(20%) 0(0.0%) 1(20%)   19(100%) 4(80%) 3.96 0.04   0(0.0%) 1(20%) 1(20%) 19(100%)   19(100%) 5(100%) - >0.99   0(0.0%) 0(0.0%) 38(100%) 9(90%) 3.88 0.04	T2Dn=19 NDn=5   19(100%) 4(80%) - - -   0(0.0%) 1(20%) 0(0.0%) 1(20%) 0(0.0%)   19(100%) 4(80%) 3.96 0.04 0.0   0(0.0%) 1(20%) 1(20%) 19(100%) 5(100%) - 0.99 -   0(0.0%) 0(0.0%) 3.88 0.04 0.0	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $

C= wild (Dominant), T=Polymorphic, T2D=Type2Diabetes, ND=Non-Diabetes(control), X<sup>+</sup>=chi-square, p=pvalue,OR=OddRatio

Tribes	lja	w	X <sup>2</sup>	Р	OR	Urh	obo	X <sup>2</sup>	Р	OR	II	ka	X <sup>2</sup>	Р	OR	lgb	0	X <sup>2</sup>	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
GG	17(89.5%)	5(100%)	-	-	-	17(89.5%)	5(100%)	-	-	-	20(100%)	4(80%)	-	-	-	20(100%)	4(80%)	-	-	-
GA	2(10.5%)	0(0.0%)				2(10.5%)	0(0.0%)				0(0.0%)	1(20%)				0(0.0%)	1(20%)			
AA	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
GG	17(89.5%)	5(100%)	0.57	0.45	0.0	17(89.5%)	5(100%)	0.57	0.45	0.0	20(100%)	4(80%)	4.17	0.04	0.0	20(100%)	4(80%)	4.17	0.04	0.0
GA+AA	2(10.5%)	0(0.0%)				2(10.5%)	0(0.0%)				0(0.0%)	1(20%)				0(0.0%)	1(20%)			
GG+GA	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
AA	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
G	36(94.7%)	10(100%)	0.55	0.45	0.0	36(94.7%)	10(100%)	0.55	0.45	0.0	40(100%)	9(90%)	4.17	0.04	0.0	40(100%)	9(90%)	4.17	0.04	0.0
А	2(5.2%)	0(0.0%)				2(5.2%)	0(0.0%)				0(0.0%)	1(10%)				0(0.0%)	1(10%)			

#### Table 16. Genotype and Allele Distribution of rs886052102 Variant of FTO genein Obese|T2D subjects in different tribes of Niger Delta

G=wild (Dominant), A=Polymorphic, T2D=Type2Diabetes, ND=Non-Type2 Diabetes (control), X<sup>2</sup>=chi-square,p=pvalue,OR=OddRatio

#### Table 17. Genotype and allele distribution of rs144743617 variant of FT ogenein obese|T2D subjectsin different tribes of NigerDelta

Tribes	lja	w	X <sup>2</sup>	Р	OR	Urh	obo	X2	Р	OR	IF	a	X <sup>2</sup>	Р	OR	lg	bo	X2	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
AA	17(89.5%)	4(80%)	-	-	-	18(94.7%)	5(100%)	-	-	-	19(95%)	5(100%)	-	-	-	20(100%)	5(100%)	-	-	-
GA	2(10.5%)	1(20%)				1(5.2%)	0(0.0%)				1(5%)	0(0.0%)				0(0.0%)	0(0.0%)			
GG	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
AA	17(89.5%)	4(80%)	0.32	0.56	2.12	18(94.7%)	5(100%)	0.27	0.60	0.0	19(95%)	5(100%)	0.27	0.60	0.0	20(100%)	5(100%)	-	>0.99	-
GA+GG	2(10.5%)	1(20%)				1(5.2%)	0(0.0%)				1(5%)	0(0.0%)				0(0.0%)	00.0%)			
AA+GA	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
GG	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
A	36(94.7%)	9(90%)	0.30	0.58	2.00	37(94.7%)	10(100%)	0.26	0.60	0.0	39(97.5%)	10(100%)	0.26	0.61	0.0	40(100%)	10(100%)	-	>0.99	-
G	2(5.2%)	1(10%)				1(5.2%)	0(0.0%)				1(2.5%)	0(0.0%)				0(0.0%)	0(0.0%)			

A= wild (Dominant), G=Polymorphic, T2D=Type2Diabetes, ND=Non-Diabetes(control), X<sup>2</sup>=chi-square,p=pvalue,OR=OddRatio

## Table 18. Genotype and allele distribution of rs886052103 variant of FTO gene in obese|T2D subjects in different tribes of Niger Delta

Tribes	lja	w	X²	Р	OR	Urho	obo	X <sup>2</sup>	Р	OR	lk	a	X²	Р	OR	lg	bo	X2	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
AA	17(89.5%)	5(100%)	-	-	-	17(89.5%)	4(80%)	-	-	-	19(95%)	5(100%)	-	-	-	20(100%)	5(100%)	-	-	-
TA	2(10.5%)	0(0.0%)				2(10.5%)	1(20%)				1(5%)	0(0.0%)				0(0.0%)	0(0.0%)			
TT	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
AA	17(89.5%)	5(100%)	0.57	0.45	0.0	17(89.5%)	4(80%)	0.32	0.56	2.12	19(95%)	5(100%)	0.27	0.60	0.0	20(100%)	5(100%)			
TA+TT	2(10.5%)	0(0.0%)				2(10.5%)	1(20%)				1(5%)	0(0.0%)				0(0.0%)	0(0.0%)			
AA+TA	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
TT	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
A	36(94.7%)	10(100%)	0.55	0.45	0.0	36(94.7%)	9(90%)	0.30	0.58	2.00	39(97.5%)	10(100%)	0.26	0.61	0.0	40(100%)	10(100%)	-	>0.99	-
Т	2(5.2%)	0(0.0%)				2(5.2%)	1(10%)				1(2.5%)	0(0.0%)				0(0.0%)	0(0.0%)			

A=wild (Dominant), T=Polymorphic, T2D=Type2Diabetes, ND=Non-Diabetes (control), X =chi-square,p=pvalue, OR=Odd Ratio

Tribes	ljav	w	X <sup>2</sup>	Р	OR	Urhobo		X²	Р	OR	lka		X <sup>2</sup>	Р	OR	lgbo		X <sup>2</sup>	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
TT	14(73.7%)	4(80%)	0.58	0.74	-	14(73.7%)	4(80%)	1.09	0.57		16(80%)	4(80%)	1.87	0.39	-	17(85%)	4(80%)	1.63	0.44	-
AT	3(15.8%)	1(20%)				2(10.5%)	1(20%)				3(15%)	0(0.0%)				2(10%)	0(0.0%)			
AA	2(10.5%)	0(0.0%)				3(15.8%)	0(0.0%)				1(5%)	1(20%)				1(5%)	1(20%)			
TT	14(73.7%)	4(80%)	0.08	0.77	0.70	14(73.7%)	4(80%)	0.08	0.77	0.70	16(80%)	4(80%)	0.00	>0.99	1.0	17(85%)	4(80%)	0.07	0.78	1.41
AT+AA	5(26.3%)	1(20%)				5(26.3%)	1(20%)				4(20%)	1(20%)				3(15%)	1(20%)			
TT+AT	17(94.7%)	5(100%)	0.57	0.45	0.00	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
AA	2(10.5%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
Т	31(81.6%)	9(90%)	0.40	0.52	0.49	30(78.9%)	9(90%)	0.63	0.42	0.41	35(87.5%)	8(80%)	0.37	0.54	1.75	36(90%)	8(80%)	0.75	0.38	2.25
A	7(18.4%)	1(10%)				8(21.1%)	1(10%)				5(12.5%)	2(20%)				4(10%)	2(20%)			

## Table 19. Genotype and allele distribution of rs9939609 Variant of FTO genein obese|T2D subjects in different tribes of NigerDelta

T=wild(Dominant),A=Polymorphic,T2D=Type2Diabetes,ND=Non-Diabetes(control),X<sup>2</sup>=chi-square,p=pvalue,OR=OddRatio

## Table 20. Genotype and allele distribution of rs8050136 variant of FTO gene in obese|T2D subjects in different tribes of Niger Delta

Tribes	ljav	w	X <sup>2</sup>	Р	OR	Urh	obo	X <sup>2</sup>	Р	OR	Ik	a	X <sup>2</sup>	Р	OR	lgt	00	X2	Р	OR
Genotype	T2Dn=19	NDn=5				T2Dn=19	NDn=5				T2Dn=20	NDn=5				T2Dn=20	NDn=5			
CC	15(78.9%)	4(80%)	-	-	-	15(78.9%)	5(100%)	-	-	-	15(75%)	5(100%)	-	-	-	18(90%)	4(80%)	-	-	-
AC	4(21.1%	1(20%)				4(21.1%	0(0.0%)				5(25%)	0(0.0%)				2(10%)	1(20%)			
AA	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
CC	15(78.9%)	4(80%)	0.002	0.95	0.9	15(78.9%)	5(100%)	1.26	0.26	0.0	15(75%)	5(100%)	1.56	0.21	0.0	18(90%)	4(80%)	0.37	0.53	2.2
AC+AA	4(21.1%	1(20%)				4(21.1%	0(0.0%)				5(25%)	0(0.0%)				2(10%)	1(20%)			
CC+AC	19(100%)	5(100%)	-	>0.99	-	19(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-	20(100%)	5(100%)	-	>0.99	-
AA	0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)				0(0.0%)	0(0.0%)			
С	34(89.5%)	9(90%)	0.002	0.96	0.9	34(89.5%)	10(100%)	1.14	0.28	0.0	35(87.5%)	10(100%)	1.38	0.23	0.0	38(95%)	9(90%)	0.35	0.55	2.1
А	4(10.5%)	1(10%)				4(10.5%)	0(0.0%)				5(12.5%)	0(0.0%)				2(5%)	1(10%)			

C=wild (Dominant), A=Polymorphic, T2D=Type 2 Diabetes, ND = Non- Diabetes (control), X<sup>2</sup> =chi-square, p= p value, OR= Odd Ratio

## 4. CONCLUSION

The study found a strong association between the variant genotype rs9939609 with obesity in Niger Delta tribes, but no significant independent association with T2D. The type 2 diabetes risk resulting from rs9939609 variant of the FTO gene in this region may be obesity mediated as evidenced by the increases observed in the BMI of the carriers of the risk allele (A). However, findings showed a significant association between some other variants with type 2 diabetes independent of body mass index, especially the rs886052102 and rs201041270 genotype variants.

Findings in this study showed no obvious disparity in the associations of FTO gene variants in the lineage groupings, disease duration, or sex, neither were there any major significant difference in pattern in the FTO genetic allelic distributions within the different tribes in the region. Findings suggest a lower risk of insulin resistance with the liaw diabetics than the other tribes and the Urhobo/Isoko showed higher levels of insulin resistance. The study also observed a higher prevalence of obesity in the Urhobo/Isoko & Ika tribes and that there were a greater number of obese subjects among the female T2D than their male counterpart, but there were more males with issues of insulin resistance/insulin insufficiency among T2D subject in the Niger Delta region of Nigeria. Knowledge of the dominant SNPs that are consistent with some specific biomarkers in some ethnic groups, may provide platform to delay its expression through informed wise choice of lifestyle change and proper dieting.

## CONSENT AND ETHICAL APPROVAL

Ethical approval and permission were sought and obtained from the ethical committee of Federal Medical Centre, Asaba. Informed consent of the participants involved was also obtained using the consent form and anthropometric data was obtained via a questionnaire.

## ACKNOWLEDGEMENTS

Authors wish to appreciate the supports of Dr Osiatuma, V. O. (MD, Federal Medical Centre, Asaba), Dr Nwajei, A. I., Oburo, N. A. (Dir. Medical Laboratory Services, FMC Asaba.), Akpati, N. N., Mrs Abiakam, C. C., Jebba, B. R. (all staff of FMC Asaba) and Mr. Bingla Sukulu-Arere of General Hospital, Bomadi, Delta State for assisting in sample collection and analysis and also, FMC Asaba management, Mr. Ekpete, Nduka, Major. Ekpete, K. O. for their financial contributions.

## **COMPETING INTERESTS**

Authors have declared that no competing interests exist.

## REFERENCES

- Merkestein M, Laber S, McMurray F, Andrew D, Sachse G, Sanderson J, et al. FTO influences adipogenesis by regulating mitotic clonal expansion. Nat Commun. 2015;6:6792.
- Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gómez-Marín C, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507(7492):371-5.
- Claussnitzer M, Dankel SN, Kim KH, Quon G, Meuleman W, Haugen C, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015;373(10):895-907.
- 4. Kim YJ, Lee HS, Kim YK, Park S, Kim JM, Yun JH, et al. Association of metabolites with obesity and Type 2 diabetes based on FTO genotype. PLOS ONE. 2016; 11(6):e0156612.
- Shahid A, Rana S, Saeed S, Imran M, Afzal N, Mahmood S. Common variant of FTO gene, rs9939609, and obesity in Pakistani females. BioMed Res Int. 2013;9:1-7.
- Han L, Tang L, Wang C, Chen Z, Zhang T, Chen S, et al. Fat mass and obesityassociated gene rs11642015 polymorphism is significantly associated with prediabetes and type 2 diabetes subsequent to adjustment for body mass index. Biomed Rep. 2014;2(5):681-6.
- 7. Peng S, Zhu Y, Xu F, Ren X, Li X, Lai M. FTO gene polymorphisms and obesity risk: a meta-analysis. BMC Med. 2011;9:71.
- Meyre D, Delplanque J, Chèvre JC, Lecoeur C, Lobbens S, Gallina S, et al. Genome-wide association study for earlyonset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet. 2009;41(2):157-9.
- Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518 (7538):197-206.

- Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889-94.
- Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316 (5829):1336-41.
- 12. Kim YJ, Lee HS, Kim YK, Park S, Kim JM, Yun JH, et al. Association of metabolites with obesity and Type 2 diabetes based on FTO genotype. Plos One. 2016;11(6):e0156612.
- Liu Y, Liu Z, Song Y, Zhou D, Zhang D, Zhao T, Yang Y, Feng G, Li J, Zhang J, Liu S, Zhang Z, He L, Xu H. Meta-analysis added power to identify variants in FTO associated with type 2 diabetes and obesity in the Asian population. Obesity. 2010;18(8):1619-24.
- 14. Nnaemeka AN. Environmental pollution and associated health hazards to host communities (case study: Niger Delta region of Nigeria). Cent Asian J Environ Sci Technol Innov. 2020;1(1):30-42.
- Adeyemo A, Chen G, Zhou J, Shriner D, Doumatey A, Huang H et al. FTO genetic variation and association with obesity in West Africans and African Americans. Diabetes. 2010;59(6):1549-54.
- Hennig BJ, Fulford AJ, Sirugo G, RaycoSolon P, Hattersley AT, Frayling TM et al. FTO gene variation and measures of body mass in an African population. BioMed Cent Med Genet. 2009;10(21):1-8.

- Adeyemo A, Chen G, Zhou J, Shriner D, Doumatey A, Huang H, et al. FTO genetic variation and association with obesity in West Africans and African Americans. Diabetes. 2010;59(6):1549-54.
- Apalasamy YD, Ming MF, Rampal S, Bulgiba A, Mohamed Z. Genetic association of SNPs in the FTO gene and predisposition to obesity in Malaysian Malays. Braz J Med Biol Res. 2012;45 (12):1119-26.
- Yang Y, Liu B, Xia W, Yan J, Liu HY, Hu L, et al. FTO genotype and T2 diabetes mellitus: spatial analysis and metaanalysis of 62 case-control studies from different regions. Genes. 2017;8(2): 70-87.
- Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-48.
- Li H, Kilpeläinen TO, Liu C, Zhu J, Liu Y, Hu C, et al. Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia. 2012;55(4): 981-95.
- Peng S, Zhu Y, Xu F, Ren X, Li X, Lai M. FTO gene polymorphisms and obesity risk: A meta-analysis. BMC Med. 2011; 9:71.
- 23. Bressler J, Kao WHL, Pankow JS, Boerwinkle E. Risk of Type 2 diabetes and obesity is differentially associated with variation in FTO in whites and African-Americans in the ARIC study. Plos One. 2010;5(5):e10521.

© 2023 Ekpete et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/97065